Conolidine’s analgesic effects stem from its interaction with non-opioid pain pathways. Contrary to opioids, which bind to µ-opioid receptors from the central anxious process, conolidine modulates alternate molecular targets. A Science Improvements research located that conolidine interacts Along with the atypical chemokine receptor ACKR3/CXCR7,